Loading…
Classification of Patients with COPD on LAMA Monotherapy Using the GOLD Criteria: Analysis of a Claims-Linked Patient Survey Study
Introduction To address the burden of chronic obstructive pulmonary disease (COPD), the Global Initiative for Chronic Obstructive Lung Disease (GOLD) recommends treatment according to classification of patients by symptom severity and exacerbation risk. This post hoc analysis of a previously reporte...
Saved in:
| Published in: | Pulmonary therapy 2019-12, Vol.5 (2), p.191-200 |
|---|---|
| Main Authors: | , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c607t-ca0e7577600a8ef93f5368b2e457e0ea5a957d80e168385eeebbeee1f3c7d5123 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c607t-ca0e7577600a8ef93f5368b2e457e0ea5a957d80e168385eeebbeee1f3c7d5123 |
| container_end_page | 200 |
| container_issue | 2 |
| container_start_page | 191 |
| container_title | Pulmonary therapy |
| container_volume | 5 |
| creator | Ray, Riju Hahn, Beth Stanford, Richard H. White, John Essoi, Breanna Hunter, Alyssa Goolsby |
| description | Introduction
To address the burden of chronic obstructive pulmonary disease (COPD), the Global Initiative for Chronic Obstructive Lung Disease (GOLD) recommends treatment according to classification of patients by symptom severity and exacerbation risk. This post hoc analysis of a previously reported claims-linked, cross-sectional survey [study 205862 (HO-16-16642)] classified patients with COPD receiving long-acting muscarinic antagonist (LAMA) monotherapy based on the GOLD 2017 categories.
Methods
Eligible patients who were ≥ 40 years of age, with ≥ 2 claims with International Classification of Diseases-10th Revision-Clinical Modification COPD diagnosis codes J40–J44 ≥ 30 days apart during the 12-month baseline period, and ≥ 2 claims for LAMA monotherapy in the 6 months prior to identification, were identified using claims data from the Optum Research Database. Patients completed a survey assessing modified Medical Research Council (mMRC) Dyspnea Scale and COPD Assessment Test (CAT) scores and demographics; clinical characteristics were assessed from claims and survey data, while exacerbation history was assessed from claims data. GOLD symptom severity classifications were low (groups A and C) for patients with low scores on both the CAT and mMRC scales (scores of |
| doi_str_mv | 10.1007/s41030-019-00099-0 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_d14f80eacb7548ceabf50b96e4f0e32f</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_d14f80eacb7548ceabf50b96e4f0e32f</doaj_id><sourcerecordid>2268839212</sourcerecordid><originalsourceid>FETCH-LOGICAL-c607t-ca0e7577600a8ef93f5368b2e457e0ea5a957d80e168385eeebbeee1f3c7d5123</originalsourceid><addsrcrecordid>eNp9kk1vEzEQhlcIRKvSP8ABWeLCZenYXtu7HJCiFNpKqVKp9Gx5d8eJw2Yd7N2iXPnluEkbKAcu_pp3HnvGb5a9pfCRAqizWFDgkAOtcgCo0vgiO2ZcFjlVhXx5WIviKDuNcZVEtOKsUOXr7IgzYLKA6jj7Ne1MjM66xgzO98RbcpNW2A-R_HTDkkznN-ckBWaT6wm59r0flhjMZkvuousXJO3IxXx2TqbBDRic-UQmvem20cUHliGJ79Yxn7n-O7ZPbHI7hnvcktthbLdvslfWdBFPH-eT7O7rl2_Ty3w2v7iaTmZ5I0ENeWMAlVBKApgSbcWt4LKsGRZCIaARphKqLQGpLHkpELGu00Atb1QrKOMn2dWe23qz0pvg1iZstTdO7w58WGgTBtd0qFta2EQyTZ36VzZoaiugriQWFpAzm1if96zNWK-xbVJNwXTPoM8jvVvqhb_XspIq_UICfHgEBP9jxDjotYsNdp3p0Y9RMy4YCK4oTdL3_0hXfgypyUnFZFnyiu2qY3tVE3yMAe3hMRT0g2P03jE62UDvHKMhJb37u4xDypM_koDvBTGF-gWGP3f_B_sbuUrMOQ</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2268839212</pqid></control><display><type>article</type><title>Classification of Patients with COPD on LAMA Monotherapy Using the GOLD Criteria: Analysis of a Claims-Linked Patient Survey Study</title><source>PubMed Central (PMC)</source><source>Springer Nature - SpringerLink Journals - Fully Open Access </source><source>Alma/SFX Local Collection</source><creator>Ray, Riju ; Hahn, Beth ; Stanford, Richard H. ; White, John ; Essoi, Breanna ; Hunter, Alyssa Goolsby</creator><creatorcontrib>Ray, Riju ; Hahn, Beth ; Stanford, Richard H. ; White, John ; Essoi, Breanna ; Hunter, Alyssa Goolsby</creatorcontrib><description>Introduction
To address the burden of chronic obstructive pulmonary disease (COPD), the Global Initiative for Chronic Obstructive Lung Disease (GOLD) recommends treatment according to classification of patients by symptom severity and exacerbation risk. This post hoc analysis of a previously reported claims-linked, cross-sectional survey [study 205862 (HO-16-16642)] classified patients with COPD receiving long-acting muscarinic antagonist (LAMA) monotherapy based on the GOLD 2017 categories.
Methods
Eligible patients who were ≥ 40 years of age, with ≥ 2 claims with International Classification of Diseases-10th Revision-Clinical Modification COPD diagnosis codes J40–J44 ≥ 30 days apart during the 12-month baseline period, and ≥ 2 claims for LAMA monotherapy in the 6 months prior to identification, were identified using claims data from the Optum Research Database. Patients completed a survey assessing modified Medical Research Council (mMRC) Dyspnea Scale and COPD Assessment Test (CAT) scores and demographics; clinical characteristics were assessed from claims and survey data, while exacerbation history was assessed from claims data. GOLD symptom severity classifications were low (groups A and C) for patients with low scores on both the CAT and mMRC scales (scores of < 10 and 0–1, respectively), and high (groups B and D) for patients with high scores on either scale (scores of ≥ 10 and 2–4, respectively).
Results
Of 433 patients included, 85.5% reported a CAT total score ≥ 10, and 45.5% reported mMRC grades 2–4. During the baseline period, 63.7% of patients had ≤ 1 moderate and 0 severe (hospitalized) exacerbations, and 36.3% had ≥ 1 severe or ≥ 2 moderate exacerbation(s). The proportions of patients with each GOLD classification were: A: 9.0%; B: 54.7%; C: 4.6%; D: 31.6%.
Conclusions
In this population, over 85% of LAMA monotherapy users have symptoms and/or exacerbation risk that may necessitate therapy escalation according to 2017 GOLD guidelines.
Funding
GlaxoSmithKline [study 205862 (HO-16-16642)].</description><identifier>ISSN: 2364-1754</identifier><identifier>EISSN: 2364-1746</identifier><identifier>DOI: 10.1007/s41030-019-00099-0</identifier><identifier>PMID: 32026409</identifier><language>eng</language><publisher>Cheshire: Springer Healthcare</publisher><subject>Bronchodilator agents ; Chronic obstructive pulmonary disease ; Classification ; COPD ; Councils ; Dyspnea ; Exacerbation ; Family Medicine ; General Practice ; GOLD ; Hospitalization ; Internal Medicine ; LAMA monotherapy ; Lung diseases ; Medical research ; Medicine ; Medicine & Public Health ; Original Research ; Patient-reported outcome measures ; Patients ; Pharmacoeconomics and Health Outcomes ; Pharmacotherapy ; Pneumology/Respiratory System ; Primary care ; Quality of Life Research ; Studies</subject><ispartof>Pulmonary therapy, 2019-12, Vol.5 (2), p.191-200</ispartof><rights>The Author(s) 2019</rights><rights>Pulmonary Therapy is a copyright of Springer, (2019). All Rights Reserved. © 2019. This work is published under http://creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c607t-ca0e7577600a8ef93f5368b2e457e0ea5a957d80e168385eeebbeee1f3c7d5123</citedby><cites>FETCH-LOGICAL-c607t-ca0e7577600a8ef93f5368b2e457e0ea5a957d80e168385eeebbeee1f3c7d5123</cites><orcidid>0000-0002-7396-9336</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6967324/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6967324/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,27901,27902,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32026409$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ray, Riju</creatorcontrib><creatorcontrib>Hahn, Beth</creatorcontrib><creatorcontrib>Stanford, Richard H.</creatorcontrib><creatorcontrib>White, John</creatorcontrib><creatorcontrib>Essoi, Breanna</creatorcontrib><creatorcontrib>Hunter, Alyssa Goolsby</creatorcontrib><title>Classification of Patients with COPD on LAMA Monotherapy Using the GOLD Criteria: Analysis of a Claims-Linked Patient Survey Study</title><title>Pulmonary therapy</title><addtitle>Pulm Ther</addtitle><addtitle>Pulm Ther</addtitle><description>Introduction
To address the burden of chronic obstructive pulmonary disease (COPD), the Global Initiative for Chronic Obstructive Lung Disease (GOLD) recommends treatment according to classification of patients by symptom severity and exacerbation risk. This post hoc analysis of a previously reported claims-linked, cross-sectional survey [study 205862 (HO-16-16642)] classified patients with COPD receiving long-acting muscarinic antagonist (LAMA) monotherapy based on the GOLD 2017 categories.
Methods
Eligible patients who were ≥ 40 years of age, with ≥ 2 claims with International Classification of Diseases-10th Revision-Clinical Modification COPD diagnosis codes J40–J44 ≥ 30 days apart during the 12-month baseline period, and ≥ 2 claims for LAMA monotherapy in the 6 months prior to identification, were identified using claims data from the Optum Research Database. Patients completed a survey assessing modified Medical Research Council (mMRC) Dyspnea Scale and COPD Assessment Test (CAT) scores and demographics; clinical characteristics were assessed from claims and survey data, while exacerbation history was assessed from claims data. GOLD symptom severity classifications were low (groups A and C) for patients with low scores on both the CAT and mMRC scales (scores of < 10 and 0–1, respectively), and high (groups B and D) for patients with high scores on either scale (scores of ≥ 10 and 2–4, respectively).
Results
Of 433 patients included, 85.5% reported a CAT total score ≥ 10, and 45.5% reported mMRC grades 2–4. During the baseline period, 63.7% of patients had ≤ 1 moderate and 0 severe (hospitalized) exacerbations, and 36.3% had ≥ 1 severe or ≥ 2 moderate exacerbation(s). The proportions of patients with each GOLD classification were: A: 9.0%; B: 54.7%; C: 4.6%; D: 31.6%.
Conclusions
In this population, over 85% of LAMA monotherapy users have symptoms and/or exacerbation risk that may necessitate therapy escalation according to 2017 GOLD guidelines.
Funding
GlaxoSmithKline [study 205862 (HO-16-16642)].</description><subject>Bronchodilator agents</subject><subject>Chronic obstructive pulmonary disease</subject><subject>Classification</subject><subject>COPD</subject><subject>Councils</subject><subject>Dyspnea</subject><subject>Exacerbation</subject><subject>Family Medicine</subject><subject>General Practice</subject><subject>GOLD</subject><subject>Hospitalization</subject><subject>Internal Medicine</subject><subject>LAMA monotherapy</subject><subject>Lung diseases</subject><subject>Medical research</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Original Research</subject><subject>Patient-reported outcome measures</subject><subject>Patients</subject><subject>Pharmacoeconomics and Health Outcomes</subject><subject>Pharmacotherapy</subject><subject>Pneumology/Respiratory System</subject><subject>Primary care</subject><subject>Quality of Life Research</subject><subject>Studies</subject><issn>2364-1754</issn><issn>2364-1746</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNp9kk1vEzEQhlcIRKvSP8ABWeLCZenYXtu7HJCiFNpKqVKp9Gx5d8eJw2Yd7N2iXPnluEkbKAcu_pp3HnvGb5a9pfCRAqizWFDgkAOtcgCo0vgiO2ZcFjlVhXx5WIviKDuNcZVEtOKsUOXr7IgzYLKA6jj7Ne1MjM66xgzO98RbcpNW2A-R_HTDkkznN-ckBWaT6wm59r0flhjMZkvuousXJO3IxXx2TqbBDRic-UQmvem20cUHliGJ79Yxn7n-O7ZPbHI7hnvcktthbLdvslfWdBFPH-eT7O7rl2_Ty3w2v7iaTmZ5I0ENeWMAlVBKApgSbcWt4LKsGRZCIaARphKqLQGpLHkpELGu00Atb1QrKOMn2dWe23qz0pvg1iZstTdO7w58WGgTBtd0qFta2EQyTZ36VzZoaiugriQWFpAzm1if96zNWK-xbVJNwXTPoM8jvVvqhb_XspIq_UICfHgEBP9jxDjotYsNdp3p0Y9RMy4YCK4oTdL3_0hXfgypyUnFZFnyiu2qY3tVE3yMAe3hMRT0g2P03jE62UDvHKMhJb37u4xDypM_koDvBTGF-gWGP3f_B_sbuUrMOQ</recordid><startdate>20191201</startdate><enddate>20191201</enddate><creator>Ray, Riju</creator><creator>Hahn, Beth</creator><creator>Stanford, Richard H.</creator><creator>White, John</creator><creator>Essoi, Breanna</creator><creator>Hunter, Alyssa Goolsby</creator><general>Springer Healthcare</general><general>Springer Nature B.V</general><general>Adis, Springer Healthcare</general><scope>C6C</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>KB0</scope><scope>M2O</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PADUT</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0002-7396-9336</orcidid></search><sort><creationdate>20191201</creationdate><title>Classification of Patients with COPD on LAMA Monotherapy Using the GOLD Criteria: Analysis of a Claims-Linked Patient Survey Study</title><author>Ray, Riju ; Hahn, Beth ; Stanford, Richard H. ; White, John ; Essoi, Breanna ; Hunter, Alyssa Goolsby</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c607t-ca0e7577600a8ef93f5368b2e457e0ea5a957d80e168385eeebbeee1f3c7d5123</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Bronchodilator agents</topic><topic>Chronic obstructive pulmonary disease</topic><topic>Classification</topic><topic>COPD</topic><topic>Councils</topic><topic>Dyspnea</topic><topic>Exacerbation</topic><topic>Family Medicine</topic><topic>General Practice</topic><topic>GOLD</topic><topic>Hospitalization</topic><topic>Internal Medicine</topic><topic>LAMA monotherapy</topic><topic>Lung diseases</topic><topic>Medical research</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Original Research</topic><topic>Patient-reported outcome measures</topic><topic>Patients</topic><topic>Pharmacoeconomics and Health Outcomes</topic><topic>Pharmacotherapy</topic><topic>Pneumology/Respiratory System</topic><topic>Primary care</topic><topic>Quality of Life Research</topic><topic>Studies</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ray, Riju</creatorcontrib><creatorcontrib>Hahn, Beth</creatorcontrib><creatorcontrib>Stanford, Richard H.</creatorcontrib><creatorcontrib>White, John</creatorcontrib><creatorcontrib>Essoi, Breanna</creatorcontrib><creatorcontrib>Hunter, Alyssa Goolsby</creatorcontrib><collection>SpringerOpen</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>ProQuest Nursing & Allied Health Database</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>ProQuest research library</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>Research Library China</collection><collection>Publicly Available Content Database (Proquest) (PQ_SDU_P3)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Pulmonary therapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ray, Riju</au><au>Hahn, Beth</au><au>Stanford, Richard H.</au><au>White, John</au><au>Essoi, Breanna</au><au>Hunter, Alyssa Goolsby</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Classification of Patients with COPD on LAMA Monotherapy Using the GOLD Criteria: Analysis of a Claims-Linked Patient Survey Study</atitle><jtitle>Pulmonary therapy</jtitle><stitle>Pulm Ther</stitle><addtitle>Pulm Ther</addtitle><date>2019-12-01</date><risdate>2019</risdate><volume>5</volume><issue>2</issue><spage>191</spage><epage>200</epage><pages>191-200</pages><issn>2364-1754</issn><eissn>2364-1746</eissn><abstract>Introduction
To address the burden of chronic obstructive pulmonary disease (COPD), the Global Initiative for Chronic Obstructive Lung Disease (GOLD) recommends treatment according to classification of patients by symptom severity and exacerbation risk. This post hoc analysis of a previously reported claims-linked, cross-sectional survey [study 205862 (HO-16-16642)] classified patients with COPD receiving long-acting muscarinic antagonist (LAMA) monotherapy based on the GOLD 2017 categories.
Methods
Eligible patients who were ≥ 40 years of age, with ≥ 2 claims with International Classification of Diseases-10th Revision-Clinical Modification COPD diagnosis codes J40–J44 ≥ 30 days apart during the 12-month baseline period, and ≥ 2 claims for LAMA monotherapy in the 6 months prior to identification, were identified using claims data from the Optum Research Database. Patients completed a survey assessing modified Medical Research Council (mMRC) Dyspnea Scale and COPD Assessment Test (CAT) scores and demographics; clinical characteristics were assessed from claims and survey data, while exacerbation history was assessed from claims data. GOLD symptom severity classifications were low (groups A and C) for patients with low scores on both the CAT and mMRC scales (scores of < 10 and 0–1, respectively), and high (groups B and D) for patients with high scores on either scale (scores of ≥ 10 and 2–4, respectively).
Results
Of 433 patients included, 85.5% reported a CAT total score ≥ 10, and 45.5% reported mMRC grades 2–4. During the baseline period, 63.7% of patients had ≤ 1 moderate and 0 severe (hospitalized) exacerbations, and 36.3% had ≥ 1 severe or ≥ 2 moderate exacerbation(s). The proportions of patients with each GOLD classification were: A: 9.0%; B: 54.7%; C: 4.6%; D: 31.6%.
Conclusions
In this population, over 85% of LAMA monotherapy users have symptoms and/or exacerbation risk that may necessitate therapy escalation according to 2017 GOLD guidelines.
Funding
GlaxoSmithKline [study 205862 (HO-16-16642)].</abstract><cop>Cheshire</cop><pub>Springer Healthcare</pub><pmid>32026409</pmid><doi>10.1007/s41030-019-00099-0</doi><tpages>10</tpages><orcidid>https://orcid.org/0000-0002-7396-9336</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2364-1754 |
| ispartof | Pulmonary therapy, 2019-12, Vol.5 (2), p.191-200 |
| issn | 2364-1754 2364-1746 |
| language | eng |
| recordid | cdi_doaj_primary_oai_doaj_org_article_d14f80eacb7548ceabf50b96e4f0e32f |
| source | PubMed Central (PMC); Springer Nature - SpringerLink Journals - Fully Open Access ; Alma/SFX Local Collection |
| subjects | Bronchodilator agents Chronic obstructive pulmonary disease Classification COPD Councils Dyspnea Exacerbation Family Medicine General Practice GOLD Hospitalization Internal Medicine LAMA monotherapy Lung diseases Medical research Medicine Medicine & Public Health Original Research Patient-reported outcome measures Patients Pharmacoeconomics and Health Outcomes Pharmacotherapy Pneumology/Respiratory System Primary care Quality of Life Research Studies |
| title | Classification of Patients with COPD on LAMA Monotherapy Using the GOLD Criteria: Analysis of a Claims-Linked Patient Survey Study |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-10T13%3A18%3A56IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Classification%20of%20Patients%20with%20COPD%20on%20LAMA%20Monotherapy%20Using%20the%20GOLD%20Criteria:%20Analysis%20of%20a%20Claims-Linked%20Patient%20Survey%20Study&rft.jtitle=Pulmonary%20therapy&rft.au=Ray,%20Riju&rft.date=2019-12-01&rft.volume=5&rft.issue=2&rft.spage=191&rft.epage=200&rft.pages=191-200&rft.issn=2364-1754&rft.eissn=2364-1746&rft_id=info:doi/10.1007/s41030-019-00099-0&rft_dat=%3Cproquest_doaj_%3E2268839212%3C/proquest_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c607t-ca0e7577600a8ef93f5368b2e457e0ea5a957d80e168385eeebbeee1f3c7d5123%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2268839212&rft_id=info:pmid/32026409&rfr_iscdi=true |